This is from Covidien's COV 1st quarter results issued this morning at 6am
Looks like the approval of Exalgo 32mg dose is going over big for Zalicus. ZLCS
"Pharmaceuticals sales of $489 million in the first quarter were essentially unchanged from last year's first-quarter sales of $490 million. Sales of Specialty Pharmaceuticals climbed sharply from those of a year ago, primarily due to the strong performance of EXALGO®(hydromorphone HCl) ER tablets and good growth for generic products that was aided by the launch of generic CONCERTA® ER tablets."
Should be a strong up day for ZALICUS
Disclosure: I am long ZLCS.